Skip to content

The Potential of Robotic-Assisted Gait Training in a Rehabilitation Setting

The Potential of Robotic-Assisted Gait Training in a Rehabilitation Settin

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07529054
Acronym
RAGT_RGB
Enrollment
40
Registered
2026-04-14
Start date
2026-01-05
Completion date
2027-12-01
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke, Robotic Assisted Gait Training, Vibration Therapy, Gait Biomechanics

Keywords

Robotic Assisted Gait Training, Functional Proprioceptive Stimulation, Gait Parameter

Brief summary

Robotic-assisted gait training (RAGT) devices, such as the Lokomat®, are commonly used to support gait rehabilitation by enabling repetitive, task-specific walking movements. The functional proprioceptive stimulation (FPS) device Vibramoov® represents a novel technology designed to stimulate proprioceptors at the muscle-tendon junction through targeted vibratory stimuli, thereby activating sensorimotor centers in the brain and potentially facilitating movement execution. The aim of this randomized controlled trial is to investigate whether Lokomat® training combined with Vibramoov® leads to greater improvements in qualitative and quantitative gait parameters in stroke patients compared with Lokomat® training alone. The study will be conducted at the Gröbming Rehabilitation Center and will include patients undergoing a four-week neurological inpatient rehabilitation program. Participants will be randomly assigned to an intervention group (Lokomat® + Vibramoov®) or a control group (Lokomat® only), with 20 patients per group. Primary outcomes include the 6-Minute Walk Test (6MWT) and spatiotemporal gait parameters. Additional assessments include functional scores, patient-reported outcome measures, and blood biomarkers. Statistical analyses will be performed depending on data distribution. A follow-up assessment evaluating EQ-5D and PHQ-4 will be conducted six months after completion of the rehabilitation program.

Detailed description

Stroke is the most common cause of physical disability in Western industrialized countries, with approximately 70% of patients experiencing moderate to severe physical impairments \[1\]. In addition to the negative impact on mobility and balance, activities of daily living are often affected \[2\]. In particular, gait impairments-manifested, for example, by reduced walking speed or shortened step length-can significantly reduce the quality of life of patients after stroke \[2,3\]. Therefore, the restoration of a physiological gait pattern in terms of both qualitative and quantitative parameters represents a key objective of post-stroke rehabilitation. In addition to conventional therapeutic approaches, robotic-assisted gait training (RAGT) devices such as the Lokomat® are frequently used \[4\]. With this device, patients are able to walk actively on a treadmill while being supported by an exoskeleton that simulates a symmetrical, bilateral gait pattern \[3\]. RAGT devices aim to improve walking by enabling a high number of repetitions of task-oriented movements, thereby facilitating the relearning of movement patterns \[5\]. Novel technologies such as the functional proprioceptive stimulation (FPS) device Vibramoov® may have the potential to enhance the effectiveness of RAGT. This therapeutic device aims to stimulate proprioceptors located at the muscle-tendon junction through targeted vibratory stimuli, thereby activating sensorimotor centers in the brain via afferent Ia fibers \[6\]. As a result, the execution of movements-for example during walking-may be facilitated. According to the manufacturer, Vibramoov® can be used during walking on level ground, during treadmill walking, or in combination with the Lokomat®. However, to date there is no research investigating the effects of Vibramoov® on gait parameters in stroke patients undergoing inpatient rehabilitation. The aim of the present study is therefore to contribute to the investigation of FPS as a potential approach to maximize the effectiveness of RAGT. The primary research question is: Does Lokomat® training combined with the Vibramoov® device have a greater effect on qualitative and quantitative gait parameters in patients after stroke compared with Lokomat® training alone? To address this research question, a randomized controlled trial will be conducted at the Gröbming Rehabilitation Center. Patients after stroke who are undergoing a four-week neurological inpatient rehabilitation program will be randomly assigned to either an intervention group or a control group. Based on data regarding the effect of RAGT on the 6-Minute Walk Test (6MWT), and accounting for potential dropouts, a sample size of 20 patients per group was calculated \[4\]. Patients in both groups will receive the conventional rehabilitation program according to the medical service profile, in which RAGT represents part of the standard treatment for stroke patients with gait impairments. Patients in the control group will perform RAGT using the Lokomat®, while patients in the intervention group will perform RAGT using the Lokomat® in combination with Vibramoov®. The extent of RAGT will be identical in both groups. The effects of the intervention will be quantified using several outcome parameters, including the 6-Minute Walk Test (6MWT) and spatiotemporal gait parameters. In addition, various functional scores and patient-reported outcome measures will be collected, and laboratory parameters and blood biomarkers will be analyzed. Depending on the distribution of the data, standard statistical methods such as the independent t-test or the Mann-Whitney U test will be applied to address the research question. A follow-up assessment six months after completion of the study (telephone interview) evaluating EQ-5D and PHQ-4 is planned.

Interventions

DEVICELokomat + Vibramoov

The conventional Robotic Assisted Gait Training is combined with vibrational stimuli which is a novel approach.

DEVICELokomat

Conventional Robotic Assisted Gait Training with the Lokomat

Sponsors

Ludwig Boltzmann Institute for Arthritis and Rehabilitation
Lead SponsorNETWORK
Reha-Zentrum Gröbming
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Participants are randomized to either the control group or the intervention group. To ensure a balanced distribution between groups, a minimization approach considering four stratification factors-age, sex, spasticity, and stroke phase-is used.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of stroke (ischemic or hemorrhagic) ≥ 3 months * Age ≥ 18a and ≤ 80a * 6MWT ≤ 200m * Barthel Index ≤ 95 * Mini Mental State Exam (MMSE) ≥ 24 * FAC: ≤ 4 * BBS): ≤49 * Modified Ashworth Scale (MAS): 0-3 for the lower extremity

Exclusion criteria

* The presence of any comorbidity or disability other than stroke that would preclude gait training * Any uncontrolled health condition for which exercise is contraindicated

Design outcomes

Primary

MeasureTime frameDescription
Spatio Temporal Gait Parameter (STGP)At baseline and 4 weeks later after interventionSTGP, such as cadence or step lenght measured in a clinical gait analysis by a pressure measuring plate.
6 Minute Walk Test (6MWT)At baseline and 4 weeks later after interventionThe 6MWT is a simple functional exercise test used to assess a person's walking capacity and endurance. It measures the distance a patient can walk in six minutes on a flat surface and reflects their submaximal level of functional capacity.

Secondary

MeasureTime frameDescription
Brain Derived Neurotrophic Factor (BDNF)At baseline and 4 weeks later after interventionBiomarker measured in the serum, which is an indicator of the amount of neuroplasticity in the central nervous system.
Routine Laboratory ParameterAt baseline and 4 weeks later after interventionRoutine laboratory parameter, such as inflammatory markers measured in the serum.
Berg Balance ScaleAt baseline and 4 weeks later after interventionAssessment for evaluation of balance and risk of falls.
Functional Ambulation Category (FAC)At baseline and 4 weeks later after interventionFAC is a clinical scale used to assess a patient's walking ability and level of assistance required for ambulation.
Patient Health Questionnaire-4 (PHQ-4)At baseline and 4 weeks later after interventionThe PHQ-4 is a brief screening questionnaire for anxiety and depression.
European Quality of Life 5 Dimensions (EQ-5D)At baseline and 4 weeks later after interventionThe EQ-5D is a standardized questionnaire used to measure health-related quality of life.

Countries

Austria

Contacts

CONTACTMaximilian Kondler, BSc, MMSc
maximilian.kondler@pv.at+43(0)3685-22323
STUDY_DIRECTORBibiane Steinecker-Frohnwieser, Priv. Doz. Mag. Dr.

Ludwig Boltzmann Institut Arthritis und Rehabilitation

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 15, 2026